undamentalytics Newsletter
Sign in

Senti Biosciences Holdings, Inc. income statement

In fiscal 2025, Senti Biosciences Holdings, Inc. reported revenue of $22,000, operating income of −$68.8m (a -312631.8% margin) and net income of −$61.4m, or −$2.73 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue34300
Research and development2228323438
General and administrative2138372626
Operating income−40−62−93−61−69
Income tax———00
Net income−55−58−71−53−61
Diluted EPS−$38.00−$4.46−$3.20−$2.41−$2.73
Diluted shares (average)1m13m22m23m22m
EBITDA−40−61−89−57−65

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Senti Biosciences Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Senti Biosciences Holdings, Inc.